Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

About - Temozolomide

By mouth: Treats brain tumors.

Injection: Treats certain types of cancer in the brain.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 21 to 34 of 34

Adult Brain Tumors Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of adult brain tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: February 28, 2014

Childhood Astrocytomas Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood astrocytomas.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: June 20, 2014

Ewing Sarcoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of Ewing sarcoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 18, 2013

Neuroblastoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood neuroblastoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 23, 2014

Nutrition in Cancer Care (PDQ®): Health Professional Version

Expert-reviewed information summary about the causes and management of nutritional problems that occur in patients with cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: June 25, 2014

Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of unusual cancers of childhood such as cancers of the head and neck, chest, abdomen, reproductive system, skin, and others.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 2, 2014

Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors).

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: March 7, 2014

Melanoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of melanoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: July 11, 2014

Advanced Breast Cancer: Diagnosis and Treatment

Breast cancer is the most common cancer for women in England and Wales, with about 37,000 new cases diagnosed and 11,000 deaths recorded in England and Wales each year. In men breast cancer is rare, with about 270 cases diagnosed, and 70 deaths in England and Wales each year. Of these new cases in women and men, around 10% are diagnosed in the advanced stages, when the tumour has spread significantly within the breast or to other organs of the body. In addition, there is a significant number of women who have been previously treated with curative intent who subsequently develop either a local recurrence or metastases. Over recent years there have been important developments in the investigation and management of these patients including new chemotherapy, and biological and hormonal agents. There is some evidence of practice variation across the country and of patchy availability of certain treatments and procedures. A clinical guideline will help to address these issues and offer guidance on best practice.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: February 2009
Show search results within this document

Nutrition in Cancer Care (PDQ®): Patient Version

Expert-reviewed information summary about the causes and management of nutritional problems that occur in patients with cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: June 24, 2014

Childhood Rhabdomyosarcoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood rhabdomyosarcoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 2, 2014

Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin

The term “cancer of unknown primary” refers to a condition in which a patient has metastatic malignancy without an identified primary source. This is a very heterogeneous disease in which the type of tumour, the extent of spread, and the outcome of treatment all vary widely. When categorising patients with cancer of unknown primary, one important factor initially considered is the cell type of origin of the metastatic disease. The majority of patients have malignancy which appears to derive from epithelial cells, and hence are regarded as having carcinoma of unknown primary. Patients with tumours of non-epithelial lineage (melanoma, sarcoma, lymphoma, germ-cell) form a distinct and important minority, since subsequent management can often be satisfactorily undertaken even in the absence of an identifiable primary source. Such patients are not considered in this guideline, since their care is adequately defined in existing guidelines for their specific tumour type. The term “carcinoma of unknown primary” (CUP) is used henceforth to refer to those patients with metastatic malignancy of epithelial, neuroendocrine or undifferentiated lineage whose investigation and management is considered within the scope of this guideline.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: July 2010
Show search results within this document

Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Economic Evaluation

Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.

Health Technology Assessment - NIHR Evaluation, Trials and Studies Coordinating Centre (UK).

Version: June 2011
Show search results within this document

Hematopoietic Stem-Cell Transplantation in the Pediatric Population [Internet]

Assess comparative benefits and harms of hematopoietic stem-cell transplantation (HSCT) versus standard therapies or disease natural history in pediatric (age ≤21 years) patients with malignant solid tumors, inherited metabolic diseases, or autoimmune diseases.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: February 2012
Show search results within this document

Systematic Reviews in PubMed

See all (112)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...